Pragma Market Research


Gynecology Drugs Market 2022 – By Therapeutics (Hormonal Therapy, Non-Hormonal Therapy), By Indication (Gynecological Cancers, Menopausal Disorder, Polycystic Ovary Syndrome, Contraception), By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And By Region, Opportunities And Strategies – Global Forecast To 2031

Gynecology Drugs Market 2022 – By Therapeutics (Hormonal Therapy, Non-Hormonal Therapy), By Indication (Gynecological Cancers, Menopausal Disorder, Polycystic Ovary Syndrome, Contraception), By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And By Region, Opportunities And Strategies – Global Forecast To 2031
Report Category: Pharma and Healthcare
SKU: PMR-110920  Published Date: 2022-08-22   Pages:227   Delivery Format:


CHOOSE LICENSE TYPE





PMR Research.

Market Executive Summary

Gynecology Drugs Market Definition



The gynecology drugs market consists of sales of gynecology drugs by entities (organizations, sole traders, and partnerships) that manufacture gynecology drugs that are used to treat gynecological diseases, which includes conditions affecting the uterus, ovaries, and their appendages.



Gynecology is the branch of medicine that deals with the health of the female reproductive system as well as diagnosis and treatment female reproductive organ diseases.  Gynecologists are physicians specialized in treating these diseases and providing well-woman health care focused on the reproductive organs.



Gynecology Drugs Market Size



The global gynecology drugs market reached a value of nearly $38,109.7 million in 2021, having increased at a compound annual growth rate (CAGR) of 3.1% since 2016. The global gynecology drugs market size is expected to grow from $38,109.7 million in 2021 to $49,481.1 million in 2026 at a rate of 5.4%. The global gynecology drugs market size is then expected to grow at a CAGR of 5.6% from 2026 and reach $64,957.5 million in 2031.



Growth in the historic period in the gynecology drugs market resulted from a rise in introduction of drugs with novel mechanisms, a rise in educational tools and awareness on menopause, a rise in long-acting reversible contraceptives, a shift in lifestyles, a rise in healthcare awareness and expenditure, government initiatives and an increase in pharmaceutical R&D expenditure. The market was restrained by lack of scientific knowledge on PCOS, safety concerns with hormonal contraceptives and hormonal replacement therapies (HRT), low healthcare access, high costs of drug approval, patent expiration of drugs, pricing pressures from regulators, and regulatory changes.  



Going forward, an increase in awareness and use of contraceptives and hormone replacement therapy (HRT), age-related increase in gynecological cancers, a rise in ovarian cancer, prevalence of gynecological diseases, a rise in healthcare expenditure and rising investment to understand the mechanisms of endometriosis and its treatment will drive the market. Factors that could hinder the growth of the market in the future include high costs of drugs.



Gynecology Drugs Market Drivers



The key drivers of the gynecology drugs market include:



Increase Awareness And Use Of Contraceptives And Hormone replacement therapy (HRT)



Hormone replacement therapy (HRT) is a treatment to relieve symptoms of menopause. It replaces hormones that are at a lower level as you approach menopause. Similarly, contraception reduces pregnancy-related morbidity and mortality, reduces the risk of developing certain reproductive cancers, and can be used to treat many menstrual related symptoms and disorders. With the efforts of the government and an increase in the literacy of women, awareness about HRT and contraceptive methods has increased. For example, in a survey by the International Journal of Reproduction, Contraception, Obstetrics and Gynecology (IJRCOG), 92.5% of women were aware of one or other method of contraception. But only 42.5% were practicing contraception. Therefore, increasing awareness, availability and use of contraceptives and HRT will drive the market in the forecast period.



Gynecology Drugs Market Restraints



The key restraints on the gynecology drugs market include:



High Costs of Drugs



High costs associated with drugs is a major issue faced by citizens of many countries. The pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, the lack of cost-effective drugs has influenced the health conditions of the population and has led to a low average life expectancy. As a result, in countries such as Chad, Macedonia, Serbia, gynecology drugs companies faced with the pressure of reducing the price of drugs. The high costs associated with drugs are putting pressure on the revenues of gynecology drugs manufacturers.



Gynecology Drugs Market Trends



Major trends influencing the gynecology drugs market include:



New Treatment Developments



The launch of gynecology drug treatments by major companies is a positive trend in the market. Due to the highly competitive nature of the market and the presence of various players, companies are focusing on new advanced drugs to manufacture and develop new treatments. For instance, in September 2021, Myovant Sciences, a UK-based biopharmaceutical company has announced that the U.S. Food and Drug Administration (FDA) accepted for review a supplemental New Drug Application (sNDA) for MYFEMBREE (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) for the management of moderate to severe pain associated with endometriosis, a disorder in which tissue that normally lines the uterus grows outside the uterus. The FDA set a target action date of May 6, 2022 for this sNDA under the Prescription Drug User Fee Act (PDUFA).  Furthermore, in April 2020, the FDA approved GlaxoSmithKline plc’s supplemental New Drug Application (sNDA) for Zejula (niraparib), an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor, as a monotherapy maintenance treatment for women with platinum-responsive advanced ovarian cancer regardless of biomarker status.



Benefits and Treatment Modalities of Menopausal Hormone Therapy



Menopausal hormone therapy (HT) practices have evolved over the last few decades, guided by the changing understanding of the treatment’s risks and benefits. Symptoms such as hot flashes, chills, and sleep problems are common during menopause, with up to 70 - 80% of women experiencing vasomotor symptoms (hot flashes and/or night sweats). Also, according to the research article published in the Journal of Menopausal Medicine in 2020, nearly 75% of women experience the symptoms of menopause between the ages of 45-55 years, which has led to a reduction in self-esteem among them. Hormone therapy is the most effective treatment for the relief of vasomotor symptoms (VMS), and it also reduces bone loss, fracture risk and can treat the genitourinary syndrome of menopause (GSM) when used locally. Different types, formulations and routes of hormone therapy are available for use in women and may confer different risks and benefits. Estrogen is the most effective treatment for VMS. Women with an intact uterus require combined progestogen therapy with estrogen for endometrial protection. For those without a uterus, estrogen alone can be used. Since the risk-benefit profile of HT treatment in symptomatic menopausal women is impacted by age, time since menopause and existing comorbidities, shared decision making is critical in determining what HT formulation and route to use and when discontinuation is appropriate. Companies are also focusing on new product launches to meet the needs of menopausal hormone therapy. For instance, in October 2018, the US FDA approved bioidentical estradiol and progesterone capsules (Bijuva) by TherapeuticsMD as hormone therapy for menopausal women suffering from moderate to severe vasomotor symptoms.



Opportunities And Recommendations In The Gynecology Drugs Market



Opportunities –The top opportunities in the gynecology drugs market segmented by therapeutics will arise in the non-hormonal therapy segment, which will gain $7,081.8 million of global annual sales by 2026. The top opportunities in the gynecology drugs market segmented by indication will arise in the other indications segment, which will gain $3,075.0 million of global annual sales by 2026. The top opportunities in the gynecology drugs market segmented by distribution channel will arise in the retail pharmacies segment, which will gain $4,345.8 million of global annual sales by 2026. The gynecology drugs market size will gain the most in the USA at $2,908.8 million.



Recommendations-To take advantage of the opportunities, The Business Research Company recommends the gynecology drugs companies to focus on development of new drugs, focus on developing antibody-drug conjugates (ADCs) targeted therapy, expand in emerging markets, scale up through merger and acquisition activity, provide competitively priced offerings, focus on securing long-term supply contracts with healthcare institutions, take initiatives to educate consumers, use big data analytics to improve marketing activities, targeting female population to spread awareness and focus on partnerships with key healthcare providers.



Gynecology Drugs Market Segmentation



The gynecology drugs market is segmented by therapeutics, by indication and by distribution channel.

By Therapeutics -

The gynecology drugs market is segmented by therapeutics into:






    • a) Hormonal Therapy

    • b) Non-Hormonal Therapy





The non-hormonal therapy segment was the largest segment of the gynecology drugs market segmented by therapeutics, accounting for 66.6% of the total in 2021. Going forward, the hormonal therapy segment is expected to be the fastest growing segment in the gynecology drugs market segmented by therapeutics, at a CAGR of 6.0% during 2021-2026.

By Indication -

The gynecology drugs market is segmented by indication into:






    • a) Gynecological Cancers

    • b) Menopausal Disorder

    • c) Polycystic Ovary Syndrome

    • d) Contraception

    • e) Others Indications





The polycystic ovary syndrome segment was the largest segment of the gynecology drugs market segmented by indication, accounting for 26.1% of the total in 2021. Going forward, others indications segment is expected to be the fastest growing segment in the gynecology drugs market segmented by indication, at a CAGR of 5.7% during 2021-2026.

By Distribution Channel -

The gynecology drugs market is segmented by distribution channel into:






    • a) Hospital Pharmacies

    • b) Retail Pharmacies

    • c) Online Pharmacies





The retail pharmacies segment was the largest segment of the gynecology drugs market segmented by distribution channel, accounting for 45.3% of the total in 2021. Going forward, online pharmacies segment is expected to be the fastest growing segment in the gynecology drugs market segmented by distribution channel, at a CAGR of 9.6% during 2021-2026.

By Geography - The gynecology drugs market is segmented by geography into:






    • o Asia Pacific

      • • China

      • • India

      • • Japan

      • • Australia

      • • Indonesia

      • • South Korea


      o North America


      • • USA


      o South America


      • • Brazil


      o Western Europe


      • • France

      • • Germany

      • • UK


      o Eastern Europe


      • • Russia


      o Middle East

      o Africa





North America was the largest region in the gynecology drugs market, accounting for 33.3% of the total in 2021. It was followed by the Asia Pacific, Western Europe, and then the other regions. Going forward, the fastest-growing regions in the gynecology drugs market will be Asia Pacific and North America where growth will be at CAGRs of 6.1% and 5.2% respectively during 2021-2026. These will be followed by Western Europe and South America, where the markets are expected to register CAGRs of 5.2% and 5.1% respectively during 2021-2026.



Gynecology Drugs Market Competitive Landscape



Major Competitors Are:




  • Merck & Co. Inc.

  • AbbVie

  • Hoffmann-La Roche Ltd.

  • GlaxoSmithKline Plc

  • Pfizer Inc



Other Competitors Include:




  • AstraZeneca plc

  • Amgen Inc.

  • Lupin Pharmaceuticals Inc.

  • TherapeuticsMD Inc.

  • Ferring Holding SA.

  • Henin Lukinz Pvt. Ltd

  • Silhos Pharma Ltd

  • Fortune Labs

  • Arsawell Lifecare

  • Gladfem

  • Medlock Healthcare

  • Adorefem

  • Pax Healthcare

  • Saphnix Lifesciences

  • Lynparza

  • BeiGene

  • Zai Lab

  • Jiangsu Yangtze River Pharmaceutical Group

  • Shanghai Fosun Pharmaceutical (Group) Co., Ltd

  • Jiangsu Hengrui Medicine Co., Ltd

  • Bayer Healthcare Co., Ltd

  • Shanghai Roche Pharmaceutical Co., Ltd

  • Boehringer Ingelheim

  • Novartis

  • Janssen

  • Bristol-Myers Squibb

  • Symbiosis

  • ChargePoint Technology

  • Premier Research

  • Veristat

  • Catalyst

  • Metrion Biosciences

  • Sengenics,

  • ACROBiosystems

  • Quotient Sciences

  • Bayer AG

  • Allergan

  • Hi-Tech Park

  • Flo Health startup company

  • EVA CLINIC

  • Ava Women

  • Miracare

  • Johnson & Johnson

  • Eli Lilly and Company

  • Instituto Biologico Argentino S.A.I.C

  • Gador SA

  • Exeltis

  • Libbs Farmaceutica Ltda

  • Spimaco

  • Jamjoom Pharma

  • Tabuk Pharmaceutical Manufacturing

  • Jazeera Pharmaceutical Industries

  • Neopharma

  • Julphar

  • Sanofi

  • Cipla

  • Ranbaxy (SA) (Pty) Ltd

  • Aspen

  • Adcock Ingram

  • Eurolab



Table of Contents

Table Of Contents




  1. 1. Gynecology Drugs Market Executive Summary

     



    2. Table of Contents



    3. List of Figures



    4. List of Tables



    5. Report Structure



    6. Introduction



    6.1. Segmentation By Geography



    6.2. Segmentation By Therapeutics



    6.3. Segmentation By Indication



    6.4. Segmentation By Distribution Channel



    7. Gynecology Drugs Market Characteristics



    7.1. Market Definition



    7.2. Market Segmentation By Therapeutics



    7.2.1. Hormonal Therapy



    7.2.2. Non-Hormonal Therapy



    7.3. Market Segmentation By Indication



    7.3.1. Gynecology Cancers



    7.3.2. Menopausal Disorder



    7.3.3. Polycystic Ovary Syndrome



    7.3.4. Contraception



    7.3.5. Others



    7.4. Market Segmentation By Distribution Channel



    7.4.1. Hospital Pharmacies



    7.4.2. Retail Pharmacies



    7.4.3. Online Pharmacies



    8. Gynecology Drugs Market Trends And Strategies



    8.1. New Treatment Developments



    8.2. Benefits and Treatment Modalities of Menopausal Hormone Therapy



    8.3. Increase In Investment In Gynecology Drugs Research



    8.4. Societal Change About Contraception In Emerging Markets



    8.5. Antibody-Drug Conjugates (ADCs) Targeted Therapy



    8.6. Strategic Collaborations And Partnerships



    8.7. Combination Therapies



    9. Impact Of COVID-19 On The Gynecology Drugs Market



    9.1. Impact On Gynecological Patient Care



    9.2. Impact On Clinical Trial Management



    9.3. Supply Chain Issues



    9.4. Future Outlook



    10. Global Gynecology Drugs Market Size And Growth



    10.1. Market Size



    10.2. Historic Market Growth, 2016 – 2021, Value ($ Million)



    10.2.1. Drivers Of The Market 2016 – 2021



    10.2.2. Restraints On The Market 2016 – 2021



    10.3. Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)



    10.3.1. Drivers Of The Market 2021-2026



    10.3.2. Restraints On The Market 2021-2026



    11. Global Gynecology Drugs Market Segmentation



    11.1. Global Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)



    11.2. Global Gynecology Drugs Market, Segmentation By Indication, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)



    11.3. Global Gynecology Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)



    12. Gynecology Drugs Market, Regional And Country Analysis



    12.1. Global Gynecology Drugs Market, By Region, Historic and Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)



    12.2. Global Gynecology Drugs Market, By Country, Historic and Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)



    13. Asia-Pacific Gynecology Drugs Market



    13.1. Asia-Pacific Gynecology Drugs Market Overview



    13.1.1. Region Information



    13.1.2. Market Information



    13.1.3. Background Information



    13.1.4. Government Initiatives



    13.1.5. Regulations



    13.1.6. Regulatory Bodies



    13.1.7. Major Associations



    13.1.8. Taxes Levied



    13.1.9. Corporate Tax Structure



    13.1.10. Investments



    13.1.11. Major Companies



    13.2. Asia-Pacific Gynecology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)



    13.3. Asia-Pacific Gynecology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)



    13.4. Asia-Pacific Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)



    13.5. Asia-Pacific Gynecology Drugs Market: Country Analysis



    13.6. China Gynecology Drugs Market



    13.7. China Gynecology Drugs Market Overview



    13.7.1. Country Information



    13.7.2. Market Information



    13.7.3. Background Information



    13.7.4. Government Initiatives



    13.7.5. Regulations



    13.7.6. Regulatory Bodies



    13.7.7. Major Associations



    13.7.8. Taxes Levied



    13.7.9. Corporate Tax Structure



    13.7.10. Investments



    13.7.11. Major Companies



    13.8. China Gynecology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)



    13.9. China Gynecology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)



    13.10. China Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)



    13.11. India Gynecology Drugs Market



    13.12. India Gynecology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)



    13.13. India Gynecology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)



    13.14. India Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)



    13.15. Japan Gynecology Drugs Market



    13.16. Japan Gynecology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)



    13.17. Japan Gynecology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)



    13.18. Japan Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)



    13.19. Australia Gynecology Drugs Market



    13.20. Australia Gynecology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)



    13.21. Australia Gynecology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)



    13.22. Australia Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)



    13.23. Indonesia Gynecology Drugs Market



    13.24. Indonesia Gynecology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)



    13.25. Indonesia Gynecology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)



    13.26. Indonesia Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)



    13.27. South Korea Gynecology Drugs Market



    13.28. South Korea Gynecology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)



    13.29. South Korea Gynecology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)



    13.30. South Korea Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)



    14. Western Europe Gynecology Drugs Market



    14.1. Western Europe Gynecology Drugs Market Overview



    14.1.1. Region Information



    14.1.2. Market Information



    14.1.3. Background Information



    14.1.4. Government Initiatives



    14.1.5. Regulations



    14.1.6. Regulatory bodies



    14.1.7. Major Associations



    14.1.8. Taxes levied



    14.1.9. Corporate tax structure



    14.1.10. Investments



    14.1.11. Major Companies



    14.2. Western Europe Gynecology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)



    14.3. Western Europe Gynecology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)



    14.4. Western Europe Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)



    14.5. Western Europe Gynecology Drugs Market: Country Analysis



    14.6. UK Gynecology Drugs Market



    14.7. UK Gynecology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)



    14.8. UK Gynecology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)



    14.9. UK Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)



    14.10. Germany Gynecology Drugs Market



    14.11. Germany Gynecology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)



    14.12. Germany Gynecology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)



    14.13. Germany Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)



    14.14. France Gynecology Drugs Market



    14.15. France Gynecology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)



    14.16. France Gynecology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)



    14.17. France Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)



    15. Eastern Europe Gynecology Drugs Market



    15.1. Eastern Europe Gynecology Drugs Overview



    15.1.1. Region Information



    15.1.2. Market Information



    15.1.3. Background Information



    15.1.4. Government Initiative



    15.1.5. Regulations



    15.1.6. Regulatory Bodies



    15.1.7. Major Associations



    15.1.8. Corporate Tax Structure



    15.1.9. Investments



    15.1.10. Major Companies



    15.2. Eastern Europe Gynecology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)



    15.3. Eastern Europe Gynecology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)



    15.4. Eastern Europe Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)



    15.5. Eastern Europe Gynecology Drugs Market: Country Analysis



    15.6. Russia Gynecology Drugs Market



    15.7. Russia Gynecology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)



    15.8. Russia Gynecology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)



    15.9. Russia Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)



    16. North America Gynecology Drugs Market



    16.1. North America Gynecology Drugs Overview



    16.1.1. Region Information



    16.1.2. Market Information



    16.1.3. Background information



    16.1.4. Government Initiatives



    16.1.5. Regulations



    16.1.6. Regulatory Bodies



    16.1.7. Taxes Levied



    16.1.8. Corporate Tax Structure



    16.1.9. Investments



    16.1.10. Major Companies



    16.2. North America Gynecology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)



    16.3. North America Gynecology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)



    16.4. North America Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)



    16.5. North America Gynecology Drugs Market: Country Analysis



    16.6. USA Gynecology Drugs Market



    16.7. USA Gynecology Drugs Overview



    16.7.1. Country Information



    16.7.2. Market Information



    16.7.3. Background Information



    16.7.4. Government Initiatives



    16.7.5. Regulations



    16.7.6. Regulatory Bodies



    16.7.7. Taxes Levied



    16.7.8. Corporate Tax Structure



    16.7.9. Investments



    16.7.10. Major Companies



    16.8. USA Gynecology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)



    16.9. USA Gynecology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)



    16.10. USA Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)



    17. South America Gynecology Drugs Market



    17.1. South America Gynecology Drugs Market Overview



    17.1.1. Region Information



    17.1.2. Market Information



    17.1.3. Background Information



    17.1.4. Regulations



    17.1.5. Regulatory Bodies



    17.1.6. Major Associations



    17.1.7. Taxes Levied



    17.1.8. Corporate Tax Structure



    17.1.9. Major Companies



    17.2. South America Gynecology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)



    17.3. South America Gynecology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)



    17.4. South America Drugs market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)



    17.5. South America Gynecology Drugs Market: Country Analysis



    17.6. Brazil Gynecology Drugs Market



    17.7. Brazil Gynecology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)



    17.8. Brazil Gynecology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)



    17.9. Brazil Drugs market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)



    18. Middle East Gynecology Drugs Market



    18.1. Middle East Gynecology Drugs Market Overview



    18.1.1. Region Information



    18.1.2. Market Information



    18.1.3. Background Information



    18.1.4. Government Initiatives



    18.1.5. Regulations



    18.1.6. Regulatory Bodies



    18.1.7. Major Associations



    18.1.8. Taxes Levied



    18.1.9. Corporate Tax Structure



    18.1.10. Investments



    18.1.11. Major Companies



    18.2. Middle East Gynecology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)



    18.3. Middle East Gynecology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)



    18.4. Middle East   Drugs market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)



    19. Africa Gynecology Drugs Market



    19.1. Africa Gynecology Drugs Market Overview



    19.1.1. Region Information



    19.1.2. Market Information



    19.1.3. Background Information



    19.1.4. Government Initiatives



    19.1.5. Regulations



    19.1.6. Regulatory Bodies



    19.1.7. Major Associations



    19.1.8. Taxes Levied



    19.1.9. Corporate Tax Structure



    19.1.10. Investments



    19.1.11. Major Companies



    19.2. Africa Gynecology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)



    19.3. Africa Gynecology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)



    19.4. Africa Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)



    20. Gynecology Drugs Global Market Competitive Landscape



    20.1. Company Profiles



    20.2. Merck & Co. Inc.



    20.2.1. Company Overview



    20.2.2. Products And Services



    20.2.3. Business Strategy



    20.2.4. Financial Overview



    20.3. AbbVie



    20.3.1. Company Overview



    20.3.2. Products And Services



    20.3.3. Business Strategy



    20.3.4. Financial Overview



    20.4. F. Hoffmann-La Roche Ltd.



    20.4.1. Company Overview



    20.4.2. Products And Services



    20.4.3. Financial Overview



    20.5. GlaxoSmithKline Plc



    20.5.1. Company Overview



    20.5.2. Products And Services



    20.5.3. Business Strategy



    20.5.4. Financial Overview



    20.6. Pfizer Inc.



    20.6.1. Company Overview



    20.6.2. Products And Services



    20.6.3. Business Strategy



    20.6.4. Financial Overview



    21. Key Mergers And Acquisitions In The Gynecology Drugs Market



    21.1. Bharat Serums & Vaccines Acquired Women Health Brand Tidilan



    21.2. Carlyle And PAI Partners Agreed To Acquired Theramex



    21.3. Organon Acquired Forendo Pharma



    21.4. Bayer Acquired KaNDy Therapeutics



    21.5. AbbVie Acquired Allergan



    21.6. Norgine Acquired Azanta



    21.7. True North Acquired Glenmark Pharmaceutical Ltd Gynecology Business



    22. Gynecology Drugs Market Opportunities And Strategies



    22.1. Global Gynecology Drugs Market In 2026 – Countries Offering Most New Opportunities



    22.2. Global Gynecology Drugs Market In 2026 – Segments Offering Most New Opportunities



    22.3. Global Gynecology Drugs Market In 2026 – Growth Strategies



    22.3.1. Market Trend Based Strategies



    22.3.2. Competitor Strategies



    23. Gynecology Drugs Market, Conclusions And Recommendations



    23.1. Conclusions



    23.2. Recommendations



    23.2.1. Product



    23.2.2. Place



    23.2.3. Price



    23.2.4. Promotion



    23.2.5. People



    24. Appendix



    24.1. Market Data Sources



    24.2. Research Methodology



    24.3. Currencies



    24.4. Research Inquiries



    24.5. The Business Research Company



    24.6. Copyright and Disclaimer





List of Figures

List Of Tables




  • Table 1: Global Gynecology Drugs Market, Historic, 2016 – 2021, $ Million

    • Table 2: Global Gynecology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

    • Table 3: Global Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Table 4: Global Gynecology Drugs market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

    • Table 5: Global Gynecology Drugs Market, Segmentation By Indication, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Table 6: Global Gynecology Drugs Market, Segmentation By Indication, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

    • Table 7: Global Gynecology Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Table 8: Global Gynecology Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

    • Table 9: Global Gynecology Drugs Market, By Region, Historic and Forecast, 2016 – 2021, 2026F, 2031F, %

    • Table 10: Global Gynecology Drugs Market, By Region, Historic and Forecast, 2016 – 2021, 2026F, 2031F, $ Million

    • Table 11: Global Gynecology Drugs Market, By Country, Historic and Forecast, 2016 – 2021, 2026F, 2031F, %

    • Table 12: Global Gynecology Drugs Market, By Country, Historic and Forecast, 2016 – 2021, 2026F, 2031F, $ Million

    • Table 13: Asia Pacific GDP Per Capita, 2015-2020, $

    • Table 14: Asia-Pacific, Population By Age Group, By Country, 2015-2025, Thousands

    • Table 15: Asia-Pacific Public Healthcare Expenditure, 2015-2020, $ Billion

    • Table 16:  Asia-Pacific Private Healthcare Expenditure, 2015-2020, $ Billion

    • Table 17: Asia-Pacific Healthcare Services Market Size, 2016-2026, $ Billion

    • Table 18: Asia-Pacific Gynecology Drugs Market, Pharmaceuticals Drugs Market Size, By Country, 2016-2026, $ Billion

    • Table 19: Asia-Pacific Gynecology Drugs Market, Historic, 2016 – 2021, $ Million

    • Table 20: Asia-Pacific Gynecology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

    • Table 21: Asia-Pacific Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Table 22: Asia-Pacific Gynecology Drugs market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

    • Table 23: China GDP Per Capita, 2015-2020, $

    • Table 24: China, Population By Age Group, 2015-2025, Thousands

    • Table 25:  China Public Healthcare Expenditure And Private Healthcare Expenditure, 2015-2020, $ Billion

    • Table 26: China Healthcare Services Market Size, 2016-2026, $ Billion

    • Table 27: China Gynecology Drugs Market, Pharmaceuticals Drugs Market Size, 2016-2026, $ Billion

    • Table 28: China Gynecology Drugs Market, Historic, 2016 – 2021, $ Million

    • Table 29: China Gynecology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

    • Table 30: China Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Table 31: China Gynecology Drugs market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

    • Table 32: India Gynecology Drugs Market, Historic, 2016 – 2021, $ Million

    • Table 33: India Gynecology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

    • Table 34: India Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Table 35: India Gynecology Drugs market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

    • Table 36: Japan Gynecology Drugs Market, Historic, 2016 – 2021, $ Million

    • Table 37: Japan Gynecology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

    • Table 38: Japan Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Table 39: Japan Gynecology Drugs market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

    • Table 40: Australia Gynecology Drugs Market, Historic, 2016 – 2021, $ Million

    • Table 41: Australia Gynecology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

    • Table 42: Australia Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Table 43: Australia Gynecology Drugs market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

    • Table 44: Indonesia Gynecology Drugs Market, Historic, 2016 – 2021, $ Million

    • Table 45: Indonesia Gynecology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

    • Table 46: Indonesia Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Table 47: Indonesia Gynecology Drugs market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

    • Table 48: South Korea Gynecology Drugs Market, Historic, 2016 – 2021, $ Million

    • Table 49: South Korea Gynecology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

    • Table 50: South Korea Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Table 51: South Korea Gynecology Drugs market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

    • Table 52: Western Europe GDP Per Capita, 2015-2020, $

    • Table 53: Western Europe, Population By Age Group, By Country, 2015-2025, Thousands

    • Table 54:  Western Europe Public Healthcare Expenditure, 2015-2020, $ Billion

    • Table 55:  Western Europe Private Healthcare Expenditure, 2015-2020, $ Billion

    • Table 56: Western Europe Healthcare Services Market Size, 2016-2026, $ Billion

    • Table 57: Western Europe Gynecology Drugs Market, Pharmaceuticals Drugs Market Size, By Country, 2016-2026, $ Billion

    • Table 58: Western Europe Gynecology Drugs Market, Historic, 2016 – 2021, $ Million

    • Table 59: Western Europe Gynecology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

    • Table 60: Western Europe Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Table 61: Western Europe Gynecology Drugs market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

    • Table 62: UK Gynecology Drugs Market, Historic, 2016 – 2021, $ Million

    • Table 63: UK Gynecology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

    • Table 64: UK Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Table 65: UK Gynecology Drugs market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

    • Table 66: Germany Gynecology Drugs Market, Historic, 2016 – 2021, $ Million

    • Table 67: Germany Gynecology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

    • Table 68: Germany Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Table 69: Germany Gynecology Drugs market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

    • Table 70: France Gynecology Drugs Market, Historic, 2016 – 2021, $ Million

    • Table 71: France Gynecology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

    • Table 72: France Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Table 73: France Gynecology Drugs market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

    • Table 74: Eastern Europe GDP Per Capita, 2015-2020, $

    • Table 75: Eastern Europe, Population By Age Group, By Country, 2015-2025, Thousands

    • Table 76:  Eastern Europe Public Healthcare Expenditure, 2015-2020, $ Billion

    • Table 77:  Eastern Europe Private Healthcare Expenditure, 2015-2020, $ Billion

    • Table 78: Eastern Europe Healthcare Services Market Size, 2016-2026, $ Billion

    • Table 79: Eastern Europe Gynecology Drugs Market, Pharmaceuticals Drugs Market Size, By Country, 2016-2026, $ Billion

    • Table 80: Eastern Europe Gynecology Drugs Market, Historic, 2016 – 2021, $ Million

    • Table 81: Eastern Europe Gynecology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

    • Table 82: Eastern Europe Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Table 83: Eastern Europe Gynecology Drugs market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

    • Table 84: Russia Gynecology Drugs Market, Historic, 2016 – 2021, $ Million

    • Table 85: Russia Gynecology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

    • Table 86: Russia Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Table 87: Russia Gynecology Drugs market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

    • Table 88: North America GDP Per Capita, 2015-2020, $

    • Table 89: North America, Population By Age Group, By Country, 2015-2025, Thousands

    • Table 90:  North America Public Healthcare Expenditure, 2015-2020, $ Billion

    • Table 91:  North America Private Healthcare Expenditure, 2015-2020, $ Billion

    • Table 92: North America Healthcare Services Market Size, 2016-2026, $ Billion

    • Table 93: North America Gynecology Drugs Market, Pharmaceuticals Drugs Market Size, By Country, 2016-2026, $ Billion

    • Table 94: North America Gynecology Drugs Market, Historic, 2016 – 2021, $ Million

    • Table 95: North America Gynecology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

    • Table 96: North America Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Table 97: North America Gynecology Drugs market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

    • Table 98: USA GDP Per Capita, 2015-2020, $

    • Table 99: USA, Population By Age Group, 2015-2025, Thousands

    • Table 100:  USA Public Healthcare Expenditure And Private Healthcare Expenditure, 2015-2020, $ Billion

    • Table 101: USA Healthcare Services Market Size, 2016-2026, $ Billion

    • Table 102: USA Gynecology Drugs Market, Pharmaceuticals Drugs Market Size, 2016-2026, $ Billion

    • Table 103: USA Gynecology Drugs Market, Historic, 2016 – 2021, $ Million

    • Table 104: USA Gynecology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

    • Table 105: USA Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Table 106: USA Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

    • Table 107: South America GDP Per Capita, 2015-2020, $

    • Table 108: South America, Population By Age Group, By Country, 2015-2025, Thousands

    • Table 109:  South America Public Healthcare Expenditure, 2015-2020, $ Billion

    • Table 110:  South America Private Healthcare Expenditure, 2015-2020, $ Billion

    • Table 111: South America Healthcare Services Market Size, 2016-2026, $ Billion

    • Table 112: South America Gynecology Drugs Market, Pharmaceuticals Drugs Market Size, By Country, 2016-2026, $ Billion

    • Table 113: South America Gynecology Drugs Market, Historic, 2016 – 2021, $ Million

    • Table 114: South America Drugs market, Forecast, 2021 – 2026, 2031F, $ Million

    • Table 115: South America Gynecology Drugs market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Table 116: South America Gynecology Drugs market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

    • Table 117: Brazil Gynecology Drugs Market, Historic, 2016 – 2021, $ Million

    • Table 118: Brazil Drugs market, Forecast, 2021 – 2026, 2031F, $ Million

    • Table 119: Brazil Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Table 120: Brazil Drugs market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

    • Table 121: Middle East GDP Per Capita, 2015-2020, $

    • Table 122: Middle East, Population By Age Group, By Country, 2015-2025, Thousands

    • Table 123:  Middle East Public Healthcare Expenditure, 2015-2020, $ Billion

    • Table 124:  Middle East Private Healthcare Expenditure, 2015-2020, $ Billion

    • Table 125: Middle East Healthcare Services Market Size, 2016-2026, $ Billion

    • Table 126: Middle East Gynecology Drugs Market, Pharmaceuticals Drugs Market Size, By Country, 2016-2026, $ Billion

    • Table 127: Middle East Gynecology Drugs Market, Historic, 2016 – 2021, $ Million

    • Table 128: Middle East Gynecology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

    • Table 129: Middle East Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Table 130: Middle East Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

    • Table 131: Africa GDP Per Capita, 2015-2020, $

    • Table 132: Africa, Population By Age Group, By Country, 2015-2025, Thousands

    • Table 133:  Africa Public Healthcare Expenditure, 2015-2020, $ Billion

    • Table 134:  Africa Private Healthcare Expenditure, 2015-2020, $ Billion

    • Table 135: Africa Healthcare Services Market Size, 2016-2026, $ Billion

    • Table 136: Africa Gynecology Drugs Market, Pharmaceuticals Drugs Market Size, By Country, 2016-2026, $ Billion

    • Table 137: Africa Gynecology Drugs Market, Historic, 2016 – 2021, $ Million

    • Table 138: Africa Gynecology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

    • Table 139: Africa Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Table 140: Africa Gynecology Drugs market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

    • Table 141: Global Gynecology Drugs Market, Key Competitor Estimated Market Shares, 2021, Percentage (%)

    • Table 142: Merck & Co. Inc. – Financial Overview, 2017 - 2021, $ Billion

    • Table 143: AbbVie – Financial Overview, 2017 - 2021, $ Billion

    • Table 144: F. Hoffmann-La Roche Ltd. – Financial Overview, 2017 - 2021, $ Billion

    • Table 145: GlaxoSmithKline Plc – Financial Overview, 2017 - 2021, $ Billion

    • Table 146: Pfizer Inc. – Financial Overview, 2017 - 2021, $ Billion

    • Table 147: Global Gynecology Drugs Market Size Gain ($ Million), 2021 – 2026, By Country

    • Table 148: Global Gynecology Drugs Market Size Gain ($ Million), Segmentation By Therapeutics, 2021 – 2026

    • Table 149: Global Gynecology Drugs Market Size Gain ($ Million), Segmentation By Indication, 2021 – 2026

    • Table 150: Global Gynecology Drugs Market Size Gain ($ Million), Segmentation By Distribution Channel, 2021 – 2026

    • Table 151: Gynecology Drugs - Market Data Sources





List Of Figures




  • Figure 1: Global Gynecology Drugs Market Segmentation By Therapeutics

    • Figure 2: Global Gynecology Drugs Market Segmentation By Indication

    • Figure 3: Global Gynecology Drugs Market Segmentation By Distribution Channel

    • Figure 4: Global Gynecology Drugs Market, Historic, 2016 – 2021, $ Million

    • Figure 5: Global Gynecology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

    • Figure 6: Global Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Figure 7: Global Gynecology Drugs Market, Segmentation By Indication, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Figure 8: Global Gynecology Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Figure 9: Global Gynecology Drugs Market, By Region, Historic and Forecast, 2016 – 2021, 2026F, 2031F, %

    • Figure 10: Global Gynecology Drugs Market, By Country, Historic and Forecast, 2016 – 2021, 2026F, 2031F, %

    • Figure 11: Asia-Pacific Gynecology Drugs Market, Historic, 2016 – 2021, $ Million

    • Figure 12: Asia-Pacific Gynecology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

    • Figure 13: Asia-Pacific Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Figure 14: China Gynecology Drugs Market, Historic, 2016 – 2021, $ Million

    • Figure 15: China Gynecology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

    • Figure 16: China Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Figure 17: India Gynecology Drugs Market, Historic, 2016 – 2021, $ Million

    • Figure 18: India Gynecology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

    • Figure 19: India Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Figure 20: Japan Gynecology Drugs Market, Historic, 2016 – 2021, $ Million

    • Figure 21: Japan Gynecology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

    • Figure 22: Japan Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Figure 23: Australia Gynecology Drugs Market, Historic, 2016 – 2021, $ Million

    • Figure 24: Australia Gynecology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

    • Figure 25: Australia Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Figure 26: Indonesia Gynecology Drugs Market, Historic, 2016 – 2021, $ Million

    • Figure 27: Indonesia Gynecology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

    • Figure 28: Indonesia Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Figure 29: South Korea Gynecology Drugs Market, Historic, 2016 – 2021, $ Million

    • Figure 30: South Korea Gynecology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

    • Figure 31: South Korea Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Figure 32: Western Europe Gynecology Drugs Market, Historic, 2016 – 2021, $ Million

    • Figure 33: Western Europe Gynecology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

    • Figure 34: Western Europe Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Figure 35: UK Gynecology Drugs Market, Historic, 2016 – 2021, $ Million

    • Figure 36: UK Gynecology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

    • Figure 37: UK Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Figure 38: Germany Gynecology Drugs Market, Historic, 2016 – 2021, $ Million

    • Figure 39: Germany Gynecology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

    • Figure 40: Germany Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Figure 41: France Gynecology Drugs Market, Historic, 2016 – 2021, $ Million

    • Figure 42: France Gynecology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

    • Figure 43: France Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Figure 44: Eastern Europe Gynecology Drugs Market, Historic, 2016 – 2021, $ Million

    • Figure 45: Eastern Europe Gynecology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

    • Figure 46: Eastern Europe Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Figure 47: Russia Gynecology Drugs Market, Historic, 2016 – 2021, $ Million

    • Figure 48: Russia Gynecology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

    • Figure 49: Russia Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Figure 50: North America Gynecology Drugs Market, Historic, 2016 – 2021, $ Million

    • Figure 51: North America Gynecology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

    • Figure 52: North America Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Figure 53: USA Gynecology Drugs Market, Historic, 2016 – 2021, $ Million

    • Figure 54: USA Gynecology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

    • Figure 55: USA Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Figure 56: South America Gynecology Drugs Market, Historic, 2016 – 2021, $ Million

    • Figure 57: South America Gynecology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

    • Figure 58: South America Gynecology Drugs market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Figure 59: Brazil Gynecology Drugs Market, Historic, 2016 – 2021, $ Million

    • Figure 60: Brazil Gynecology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

    • Figure 61: Brazil Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Figure 62: Middle East Gynecology Drugs Market, Historic, 2016 – 2021, $ Million

    • Figure 63: Middle East  Gynecology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

    • Figure 64: Middle East Gynecology Drugs market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Figure 65: Africa Gynecology Drugs Market, Historic, 2016 – 2021, $ Million

    • Figure 66: Africa Gynecology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

    • Figure 67: Africa Gynecology Drugs Market, Segmentation By Therapeutics, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

    • Figure 68: Global Gynecology Drugs Market, Key Competitor Estimated Market Shares, 2021, Percentage (%)

    • Figure 69: Merck & Co. Inc. – Financial Overview, 2017 – 2021, $ Billion

    • Figure 70: AbbVie – Financial Overview, 2017 – 2021, $ Billion

    • Figure 71: F. Hoffmann-La Roche Ltd. – Financial Overview, 2017 – 2021, $ Billion

    • Figure 72: GlaxoSmithKline Plc – Financial Overview, 2017 – 2021, $ Billion

    • Figure 73: Pfizer Inc. – Financial Overview, 2017 – 2021, $ Billion




We can offer customized data and information to meet our clients need.

This report focuses on:

► Intelligent insights to take informed business decisions.

► Qualitative and quantitative analysis of the market.

► Market size and forecasts from 2024 to 2030.

► Opportunities for expansion and in-depth market analysis.

► Segmentation and regional revenue forecasts.

► Analysis of the market share and competitive landscape.

► Strategic recommendations for future growth.


You'll also receive:

► A comprehensive market research report in PDF or PPT formats.

► Access to our analysts to learn more about the report and get answers to your specific business questions.

► The option to customize the report to meet your specific needs, such as adding more countries or regions or developing abusiness case to launch a new product.


Contact us today to learn more and get sample report.


Our Research Reports Look Like This
Pragma Market Research Sample

Covid-19 Impact Duns and Brad Badge
up